Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test

NCT ID NCT07732387

Not yet recruiting Symptom relief Sponsor: Yanping Kong Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This early-stage trial tests a new fixed-dose combination pill called Viaca, which contains sildenafil and cabergoline, for erectile dysfunction. The study enrolls 30 healthy adult male volunteers to compare the safety, tolerability, and drug levels of the combination against each drug taken alone. By targeting both vascular and neuroendocrine pathways, the combination aims to work effectively at lower doses of each component.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a fixed-dose combination of sildenafil and cabergoline (Viaca)
What this could lead to: If safe and well-tolerated, this combination could offer a new treatment option for erectile dysfunction that works through two different pathways, possibly at lower doses.
What could go wrong: This is an early Phase 1 safety study in only 30 healthy volunteers, not people with ED. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERECTILE DYSFUNCTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

erectile dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ERECTILE DYSFUNCTIONS HEALTHY VOLUNTEER

Contacts and locations

Locations

Nucleus Network Brisbane

Herston, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.